Back to search

National and Kapodistrian University of Athens

Η φαρμακογενής υπερπρολακτιναιμία σε σχιζοφρενικούς αρρώστους: ελεγχόμενη μελέτη της ντοπαμινικής υπόθεσης

Abstract

dc:description

A great deal of factors can cause sexual dysfunction in schizophrenic patients. The disease itself,as well as the use of antipsychotic medication. Antipsychotic medications are associated todifferent degrees with sexual dysfunction mainly through their potential to inducehyperprolactinemia. Prolactin (PRL) secretion is mainly regulated by the hypothalamicdopaminergic systems. Hyperprolactinemia may cause oligomennorrhea, amenorrhea,galactorrhea, gynecomastia, oligospermia, osteoporosis and cancer. It also affects libido, arousaland orgasm.Current guidelines for the management of treatment-emergent hyperprolactinemia, primarilyrecommend dose reduction of antipsychotic medication or switch to a PRL- sparing agent andalternatively the use of dopamine agonists. The dilemma becomes more challenging in clinicallystable patients who have been well maintained for a long period on their current antipsychoticmedication and for whom a change in treatment might cause the appearance of side effects andpossibly ultimately the termination of treatment. We therefore conducted this 6-month,parallel-group study to prospectively investigate the effects of the dopamine agonistcabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP194) and hyperprolactinemia (PRL>20 ng/ml for men and PRL>25 ng/ml for women), wellmaintained on a PRL- raising antipsychotic (risperidone, amisulpride or haloperidole) . The mainobjective was to investigate whether cabergoline (CBG) improved on sexual functioning inpatients with hyperprolactinemia, without having unfavorable effects on their psychopathology.In total 80 patients were enrolled; 33 were receiving risperidone, 17 haloperidol, 11amisulpride, and 8 risperidone microspheres long acting. Based on PRL levels (<50, 50−99, or >100 ng/ml), patients were assigned in three cabergoline doses (0.25, 0.5 and 1 mg/day in 38,23, and 19 patients respectively). The psychopathology was evaluated using the Positive andNegative Syndrom Scale (PANSS), and sexual dysfunction with the Arizona Sexual ExperiencesScale (ASEX), the Sexual Functioning Questionnaire and the Sexual Behaviour Questionnaire. Thedosage of the antipsychotic medication remained stable throughout the study.In the whole sample CBG brought about a reduction in the PRL levels in all patients, from 73.3(±46.8) to 42.0 (±27.8) at month 3 and 27.1 (±20.4) at month 6 (p<0.001). ASEX scores declinedfrom 19.1 (5.1) to 17.6 (5.5) at month 3 and 15.0 (6.5) at month 6 (p<0.001). The decrease inPRL levels and in ASEX scores was statistically significant between groups. PANSS scores werereduced in the 3rd and 6th month (p=0.001at 6 month vs. baseline). There was no unfavorabledevelopment in the psychopathology of the patients. The females had also an improvement inthe menstruation cycle.Our main finding is that cabergoline administration to clinically stable patients withschizophrenia may improve sexual functioning without adversely affecting theirpsychopathologic status, provided that the dose has been suited to the severity of thehyperprolactinemia. To our knowledge, the present study provides the first longitudinal data onthe clinical management of antipsychotic - induced hyperprolactinemia and sexual function, inschizophrenic patients treated with cabergoline (CBG).

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kalkavoura, Christina
  • Καλκαβούρα, Χριστίνα

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/39148

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kalkavoura, Christina; Καλκαβούρα, Χριστίνα. Η φαρμακογενής υπερπρολακτιναιμία σε σχιζοφρενικούς αρρώστους: ελεγχόμενη μελέτη της ντοπαμινικής υπόθεσης. National and Kapodistrian University of Athens, 2013. http://hdl.handle.net/10442/hedi/39148